SynthesisJournal of cancer research and clinical oncology2023

Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.

Si Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.